In this micro learning programme, you'll learn about PARP inhibitors in prostate cancer from independent experts Assoc. Prof. Alicia Morgans and Dr Pasquale Rescigno. 

Learning resources include videos, slides, flashcards and assessments. Complete both modules to earn your CME credit.

What you'll learn

 


Clinical takeaways:

  • PARP inhibitors are effective drugs as monotherapy in mCRPC patients with HRR alterations
  • Genetic testing is important to help with treatment decision-making and for understanding inherited risk
  • BRCA mutations are associated with poor outcomes in mCRPC patients
  • Patients with tumours harbouring BRCA1/BRCA2 alterations appear to derive the greatest clinical benefit from PARPi, but patients with other HRR alterations also derive benefit
  • PARP inhibitors combined with novel hormonal agents are effective as a first-line treatment option for mCRPC patients with an HRR mutation. Certain combinations, such as olaparib plus abiraterone, have also shown benefits in patients regardless of their HRR status

Dr Morgans is Genitourinary Medical Oncologist at Dana-Farber Cancer Institute, and Faculty in Medicine at Harvard Medical School in Boston, MA. She completed medical school and residency at the University of Pennsylvania School of Medicine, fellowship in Hematology/Oncology at Harvard’s Dana Farber Cancer Institute and Massachusetts General Hospital Cancer Center in Boston and earned a Master of Public Health at Vanderbilt University. Dr Morgans treats patients with prostate, bladder, and testicular cancer, and her research assesses complications of advanced prostate cancer survivorship and patient-centered treatment decision-making in advanced prostate cancer.

Assoc. Prof. Alicia Morgans has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Myovant, Novartis, Pfizer, Sanofi and Telix. 

Dr Pasquale Rescigno is Clinical Senior Lecturer at the Translational and Clinical Research Institute at Newcastle University, UK. He is the former Head of the Translational and Clinical Trial Team on GU Cancers at the Istituto di Candiolo FPO-IRCCS (Candiolo Cancer Institute), Clinical Research Fellow at the Institute of Cancer Research (London), and Prostate Cancer Foundation Young Investigator awardee.  

His research mainly focuses on the study of mechanisms/pathways that are disrupted in prostate cancer (such as PTEN/PI3K/AKT, TP53 and RB1), and on the identification and validation of predictive, prognostic and efficacy-response biomarkers for novel agents targeting the PI3K/AKT, DNA repair systems and the PD-1/PDL-1 pathways.

He has served as Principal and Sub-investigator of several phase I/II/III Clinical Trials and designed and is the Clinical Coordinator and Principal Investigator of UK and Italian national research projects (MAESTRO, an umbrella trial and PERSEUS1 in the UK; BITCOIN and BRIDGE in Italy).

More recently, his research activity focused on the study of gut microbiome in prostate cancer.
Programme summary
Take the micro learning now
Other modules in this series
PARP inhibitors in prostate cancer and the rationale behind combination treatment

PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

PARP inhibitors in prostate cancer and the rationale behind combination treatment

PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Current Module
Share this programme
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
Accreditation and Endorsement
EACCME
This course has been accredited by EACCME® for 0.5 ECMEC®.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Prostate cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resouces
  • clock 30 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Experts
Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
conference-update Conference update
Oncology 
GI highlights from ESMO 2023

An expert panel discussion hosted by COR2ED and eChinaHealth

  • clock 50 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from BeiGene Europe and SystImmune.
conference-update Conference update
Oncology 
RCC Update from ESMO 2023

How will the latest data impact clinical practice?

Experts
Prof. Laurence Albiges
  • download Downloadable
    Resouces
  • clock 4 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Eisai Europe Limited.
conference-update Conference update
Oncology 
Lung cancer highlights from ESMO 2023

An expert panel discussion hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
conference-update Conference update
Oncology 
Precision Oncology Update From ESMO 2023

How will the latest data impact clinical practice?

Experts
Dr Philipp Ivanyi
  • download Downloadable
    Resouces
  • clock 3 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Bayer.